why am i throwing up on semaglutide GLP-1 nausea: How to handle GLP-1s' most common side effect Semaglutide Nausea: 11 Tips to

Description

Rising R&D costs, longer cycles, and blockbuster drugs shape 2024s innovation landscape.

Metseras pipeline includes MET-097i, a GLP-1 receptor agonist designed for once-monthly dosing, and MET-233i, an amylin analog being developed for monthly administration

Daniel Drucker: GLP-1 medicines beyond diabetes and obesity with benefits for heart, kidney, liver, sleep apnea, substance use disorders, and even neurodegenerative diseases

IQVIA MedTech provides the data and insights to help you assess the potential impact on your business and make informed decisions for the future

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk